314BR, Associate Director / Senior Manager, Analytical Development

Job Code 314BR


Fate Therapeutics is seeking a highly-motivated individual with a breadth of analytical development expertise to provide scientific and technical leadership to the analytical and assay development team. The successful candidate will be responsible for establishing analytical strategies and techniques in support of process and product development of engineered iPSC-derived NK and T cell therapies and the development and implementation of best-in-class analytical testing strategies to control and characterize Fate’s products. Operating in a cross-functional and dynamic environment, the individual will partner with Process Development, Quality Control, Manufacturing Sciences and Technology, Product Development, Regulatory Affairs, and Manufacturing teams. The ideal candidates should have experience managing daily operations of a team, a proven track record of providing leadership to accelerate clinical product development, and implementing analytical testing methods that are compliant with regulatory requirements. This is a full-time position reporting to the Director, Process and Assay Development and is located at our corporate headquarters in San Diego.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 314BR.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.